Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Colorectal cancer (CRC) is a significant global health burden.
• Bevacizumab is approved for metastatic CRC (mCRC), but real-world data on its effectiveness and safety are limited.
• This study addresses the need for real-world evidence in Romania.

Purpose of the Study:

• To assess the outcomes and safety of bevacizumab in mCRC patients in a Romanian real-world setting.
• To analyze progression-free survival (PFS), overall survival (OS), and adverse events.
• To identify factors influencing treatment outcomes.

Main Methods:

• Observational, retrospective, multicentric cohort study in Romania.
• Included 554 mCRC patients treated with bevacizumab in routine clinical practice (2008-2018).
• Endpoints: PFS, OS, adverse events, and patterns of bevacizumab use.

Main Results:

• Median PFS: 8.4 months (first-line) and 6.6 months (second-line).
• Median OS: 17.7 months (first-line) and 13.5 months (second-line).
• Primary tumor resection correlated with longer PFS and OS; safety profile was as expected.

Conclusions:

• Bevacizumab demonstrated a generally expected safety profile in this real-world mCRC cohort.
• While PFS was comparable to trial data, OS was shorter, potentially due to treatment sequencing and patient characteristics.
• Resection of the primary tumor was associated with improved overall survival in bevacizumab-treated mCRC patients.